and chemotherapy. Shh and Wnt subgroups show the highest overall survival while group 4 and, to a higher extent, group 3 MBs are of poor prognosis with a strong tendency to form metastasis. 2, 3 Although the overall survival at 5 years reaches 70% in all MB types taken together, even peaking over 90% in the Wnt group, toxic effects due to the treatments often lead to irreversible damages that severely hamper the children's cognitive development and general quality of life. In particular, RT dose and age of exposure to RT are well-documented risk factors for long-term cognitive impairments in MB survivors. [7] [8] [9] Reducing RT doses has been proposed; however, it is unsuitable for high-risk MBs. 8, 9 Moreover, recurrences are fatal in a large majority of cases and are characterized by strong divergence of the relapsed tumours as compared to the initial tumours. 10 A challenge therefore lies in finding new treatments that combine high efficacy and little toxicity. Personalized targeted therapy appears to be a promising approach in this context. 11, 12 Clinical trials involving Shh pathway targeted inhibitors have enrolled Shh group MB patients based on this assertion. To date, these trials have not led to the expected results as they have induced unbearable toxicity and tumour resistance to the treatment. [13] [14] [15] All these features support the need to develop and design novel therapies against alternative targets.
Rapidly growing tumours experience an increased demand for nutrients in order to sustain their proliferative metabolism. Up-regulation of processes related to the supply of glucose, amino acids, and lipids is thus a hallmark of cancer metabolism. 16, 17 Essential amino acids (EAAs), which cannot be synthetized de novo by human cells, are absolutely required for cancer cell proliferation. Indeed, some of these nutrients can also be converted to essential metabolite intermediates of the TCA cycle, further participating in tumour energy metabolism and macromolecule synthesis. Notably, catabolism of the branched chain EAA subclass (leucine, isoleucine and valine) is required for growth of some brain tumours. 18 In addition, leucine is an essential signalling molecule required to sustain the activation of mTORC1, the master kinase of protein, lipid, nucleotide syntheses and cell proliferation. 19, 20 Therefore, considering the high expression of LAT1 in MB cells, 21 we have suggested that targeting EAA uptake might be an innovative strategy for MB treatment. The L-type amino acid transporter 1, LAT1 (SLC7A5), is a 12-transmembrane protein responsible for Na + -independent transport of large neutral EAA (Leu, Val, Ile, Phe, Trp, His, Met, Tyr) in tight association with chaperone CD98 (SLC3A2). LAT1 is an obligatory exchanger with the uptake of one amino acid (AA) being coupled to the efflux of another.
LAT1 is overexpressed in aggressive human cancers including MB and has been described as a potential therapeutic target. 21, 22 In a previous study, we demonstrated that LAT1 activity is essential for tumour growth. 23 Indeed, genetic disruption of LAT1 in colorectal and lung adenocarcinoma cell lines leads to EAA starvation, mTORC1
inactivation and growth arrest. 23, 24 In addition, our lab with others demonstrated that treatment with JPH203, a specific inhibitor that targets LAT1 and no other LAT, recapitulates these effects in several cancer cell lines, including glioma cell lines. 23, 25, 26 However, the efficiency of this compound had never been addressed in MB. In this study, we demonstrate that LAT1 is the main leucine transporter in two independent cell lines isolated from Shh (DAOY) and Group 3 (HD-MB03) MBs. 27, 28 We subsequently show that JPH203 treatment disrupts AA homeostasis, mTORC1 activity as well as proliferation and survival of both MB cell lines. Furthermore, in contrast to its effect on MB cell lines, JPH203 displays low toxicity on two normal cerebral cell types. Finally, we show that although MB cells try to adapt to a JPH203 chronic treatment by up-regulating the expression of AA transporters, no resistant clones could be isolated from the cell populations. Altogether our in vitro results strongly suggest that JPH203 is a promising therapeutic candidate for treating MB.
| MATERIAL S AND ME THODS

| Cell culture and pharmacological inhibitor
The murine cerebellar astrocyte cells C8-D1A were obtained from the 
| Immunoblotting
Cells were lysed in 1.5× Laemmli buffer, and protein concentra- 
| L-[14C]-Leucine uptake
Cells ( 
| Proliferation and viability assays
The different cell lines (2. 
| Three-dimensional growth assay
DAOY and HD-MB03 3-D cultures were prepared using ultra-low attachment 96-well plates (Corning). Cells (5000) were seeded in 200 µL medium per well. The spheroids were cultured for 8 days and pictures were taken with an AMG Evos microscope 40x objective (Thermo Fisher Scientific Inc). Spheroid areas were measured using ImageJ 1.51j8 software (National Institute of Health). 30 
| Scratch assay
DAOY cells (800 000) were seeded in 60 mm diameters and grew until they reached confluency (2 days). A wound was then done in the monolayer by scratching it with a 10 µL pipette tip (Starlab).
The culture medium was then replaced by fresh medium containing DMSO or the indicated concentrations of JPH203. Paired measurements of the wound width were done at 0 and 8 hours at six different places for each condition.
| Quantitative real-time PCR
DAOY and HD-MB03 (250 000 and 500 000 cells respectively) were seeded in 6-well plates in triplicate. 
| Statistical analysis
Data are expressed as mean ± SD. Each experiment was performed at least three times. Statistical analysis was done with the unpaired Student's t test. Differences between groups were considered statistically significant when P < 0.05 in a Student's t test. we investigated the effects of LAT1 inhibition on the two AA-sensing pathways: GCN2 and mTORC1 ( Figure 1C) . 31 In both cell lines, LAT1 inhibition resulted in the activation of the AA stress response pathway GCN2, observed through increased phosphorylation of GCN2 and EIF2α and up-regulation of ATF4 expression ( Figure 1C and Figure S1 ). Moreover, JPH203 treatment resulted in a strong decrease in mTORC1 activity, scored by the phosphorylation of its two effectors: p70-S6K1 and the ribosomal protein S6 ( Figure 1C and Figure S1 ). Altogether these results demonstrate that JPH203 treatment leads to AA starvation and suggest that LAT1 activity is required for AA homeostasis in cells belonging to different MB subgroups.
| RE SULTS
| LAT1 is the main Na
| Pharmacological inhibition of LAT1 impairs MB cell proliferation, survival and migration abilities
We next assessed the effect of JPH203-induced LAT1 pharmacological inhibition on cell proliferation and cell viability. Finally, we tested the effect of LAT1 on the migration capacities of MB cells using a scratch assay on a confluent layer of DAOY cells.
JPH203 treatment resulted in a 25% reduction in scratch closure after 8 hours compared to cells treated with DMSO ( Figure 3A,B) .
This suggests that LAT1 activity is required to sustain MB cell motility. Altogether, these findings demonstrate that LAT1 through its EAA transport activity promotes some of the key malignant features of MB cells while bearing seemingly no or low toxicity towards healthy cerebral cells.
| Chronic treatment of MB cells with JPH203 induces cellular adaptation but no resistance
In order to test the development of resistance mechanisms, HD-MB03 and DAOY cell lines were incubated for more than 120 days in JPH203-supplemented medium (20 and 30 µmol/L). The levels of LAT1 and its chaperone CD98 were dramatically increased in response to chronic exposure to JPH203 ( Figure 4A ). Consistently, the mRNA levels of LAT1 and LAT3 were also increased ( Figure S1 ).
Nonetheless, JPH203 still displayed strong anti-proliferative and cytotoxic effects on both cell lines ( Figure 4B,C) . These results strongly suggest that this 4-month adaptation was insufficient to induce resistance to LAT1 inhibition although the chronic treatment with JPH203 led to up-regulation of some components of the amino acid transport machinery.
| D ISCUSS I ON
The most aggressive forms of MBs as well as local or metastatic relapses generally show a high degree of resistance to classical treatments. It is therefore crucial to discover new treatments presenting important properties such as selective toxicity towards cancer cells and low toxicity towards normal tissues. JPH203 is a tyrosine analogue that inhibits LAT1 with a high specificity as compared to other compounds. 22, 26 The proposed mode of action of this compound is via competition with other substrates of the LAT1 transporters. 22 In this study, we show that JPH203-induced blocking of LAT1-dependent EAA transport efficiently disrupts AA homeostasis, mTORC1 activity, proliferation and survival of two independent MB cell lines isolated from MBs of different subgroups (high risk Shh group and group 3). 32 This suggests that 
23
Since leucine is an essential amino-acid, these cells cannot grow in the absence of LAT1 activity. Although our results suggest a low toxicity of JPH203 towards normal cells, it is important to mention that the impairment of the transport of branched-chain amino acids at the blood-brain barrier caused by a LAT1 deficiency has also been described to cause autism spectrum disorders in mice. 33 Hence, families, namely OATP1B1, OATP1B3, OATP2B1 and OAT3. 35 Interestingly, some of these transporters were also described to be expressed in brain capillary endothelial cells constitutive of the blood-brain barrier (BBR). 36 This suggests that a route for JPH203
to cross the BBR could be provided by transmembrane transporters, making brain tumours accessible to this compound. Alternatively, delivery of anticancer compounds into the brain can be achieved using Ommaya reservoirs. These medical devices allow intraventricular injection of the drugs, even in very young patients. 
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